Interferon-γ Pretreated Human MSC Show Improved Efficiency in Humanized Mice Model of Pulmonary Fibrosis

Ming Liu,Ke Ni,Jian Zheng
DOI: https://doi.org/10.1183/13993003.congress-2016.pa782
2016-01-01
Abstract:Pulmonary fibrosis (PF) is a devastating and lethal pathological process with limited therapeutic options. Mesenchymal stem cells (MSCs) are recently considered as an attractive treatment choice for PF. However, the better strategies for MSCs application and mechanisms need to be further investigated. Studies show that inflammation status determines the immunomodulation fate of MSCs, and Interferon-gamma (IFN-γ) is known to enhance the immunosuppressive properties of MSCs. In the present study, By using our established Bleomycin-induced humanized mice model of PF, We demonstrate that mice treated with conditioned medium (CM) from IFN-γ pretreated human bone marrow MSCs (MSC-γ-CM) show an increase in body weight, better survival rates, decreased histological lesions, inflammation score, collagen deposition and α-SMA expression in the lung tissue compared with MSC-CM treated mice. In vitro study, MSCs pre-stimulated with human recombinant IFN-γ show a significant increase of IP-10 and IDO levels in the conditioned medium (P<0.01). Compared to control MSCs, IFN-γ–licensed MSCs significantly inhibite CD3+IFN-γ+ subsets (P<0.05), which is partly blocked by addition of Celecoxib. Co-culture of lung fibroblasts from PF patients with IFN-γ-pretreated MSCs show a significantly increased inhibitory effect on α-SMA and fibronectin expression in PF patients9 lung fibroblasts, whereas addition of Celecoxib or IP-10 nueutralizing antibody is able to reverse the efficacy. These suggest that human MSCs pretreated IFN-γ show improved efficiency of inflammation and fibrosis in humanized mice model by increasing IDO and IP-10, which can emerge as a promising strategy for future clinical trials.
What problem does this paper attempt to address?